-
公开(公告)号：US20240199613A1
公开(公告)日：2024-06-20
申请号：US18550486
申请日：2022-03-16
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Nikolaos PAPAIOANNOU , Jeremy Mark TRAVINS , Sarah Jocelyn FINK , John Mark ELLARD , Alastair RAE , Stuart Shane RANKIN , Robert Staurt Laurie CHAPMAN
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
-
公开(公告)号：US12005054B2
公开(公告)日：2024-06-11
申请号：US17320574
申请日：2021-05-14
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Zacharia Cheruvallath , Jason Green , Ben Johnson , Kristin Schleicher , Huikai Sun , Mingnam Tang
IPC: A61K31/4439 , A61K31/40 , A61K31/4355 , A61K31/438 , A61K31/4468 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , C07D207/14 , C07D211/58 , C07D401/12 , C07D401/14 , C07D403/12 , C07D491/048
CPC classification number: A61K31/4439 , A61K31/40 , A61K31/4355 , A61K31/438 , A61K31/4468 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , C07D207/14 , C07D211/58 , C07D401/12 , C07D401/14 , C07D403/12 , C07D491/048
Abstract: Disclosed are compounds of Formula 1,
stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.-
公开(公告)号：US20240173323A1
公开(公告)日：2024-05-30
申请号：US18264489
申请日：2022-02-04
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Akihiro OHASHI , Kenichi IWAI , Tadahiro NAMBU , Jie YU , Kurt ENG , Michael Joseph KURANDA
IPC: A61K31/519 , A61K31/454 , A61K31/502 , A61P35/00
CPC classification number: A61K31/519 , A61K31/454 , A61K31/502 , A61P35/00
Abstract: The present disclosure relates to the treatment of cancer using a combination therapy comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, and one or more PARP inhibitors. Compound I.
-
公开(公告)号：US20240165118A1
公开(公告)日：2024-05-23
申请号：US18427579
申请日：2024-01-30
Inventor： Brendan Mark JOHNSON , Lynn SEELY , Paul N. MUDD, JR. , Susan WOLLOWITZ , Mark HIBBERD , Masataka TANIMOTO , Vijaykumar Reddy RAJASEKHAR , Mayukh Vasant SUKHATME
IPC: A61K31/519 , A61K9/00 , A61K31/513 , A61K31/565 , A61K31/57 , A61P15/00
CPC classification number: A61K31/519 , A61K31/513 , A61P15/00 , A61K9/0053 , A61K31/565 , A61K31/57
Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.
-
公开(公告)号：US20240158740A1
公开(公告)日：2024-05-16
申请号：US18281442
申请日：2022-03-08
Applicant: National University Corporation Tokyo Medical and Dental University , Takeda Pharmaceutical Company Limited
Inventor： Takanori TAKEBE , Norikazu SAIKI
CPC classification number: C12N5/0605 , C12N5/069 , C12N2501/999 , C12N2506/45
Abstract: The present invention provides the following method as an approach for enriching desired cells, particularly, yolk sac mesoderm cells or amniotic ectoderm cells, contained in an embryogenesis region-specific micropattern structure of a cell cluster formed by differentiation-inducing factors from a colony of pluripotent stem cells such as iPS cells: a method for producing a cell cluster enriched in desired cells from pluripotent stem cells, comprising the step of two-dimensionally culturing the pluripotent stem cells under Wnt signal regulation. The present invention provides, for example, a method for producing a cell cluster enriched in yolk sac mesoderm cells from pluripotent stem cells, comprising the step of two-dimensionally culturing the pluripotent stem cells under conditions that activate Wnt signals, and a method for producing a cell cluster enriched in amniotic ectoderm cells from pluripotent stem cells, comprising the step of two-dimensionally culturing the pluripotent stem cells under conditions where Wnt signals have been suppressed.
-
Patent Agency Ranking
公开(公告)号：US11969703B2
公开(公告)日：2024-04-30
申请号：US17476621
申请日：2021-09-16
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Robert Toso , Richard Spanggord , Mei Tan , Van Taiariol , Yekaterina Lin
CPC classification number: B01J19/18 , B01D29/01 , B01F27/13 , B01F35/451 , B01F35/712 , B01J8/006 , B01J19/0066 , B01J2208/00805 , B01J2208/00858
Abstract: An antibody-resin coupling apparatus quickly and efficiently activates resin beads and couples them to antibodies, while preventing breakdown and crosslinking of the beads, thereby improving downstream column purification processes, extending the usable life of the resin beads, and increasing molecule capture efficiency of the resultant resin-antibody complexes, to allow improved isolation and purification of factor VIII molecules or other drug compounds.
-
公开(公告)号：US20240125767A1
公开(公告)日：2024-04-18
申请号：US17769452
申请日：2020-10-16
Applicant: Public University Corporation Yokohama City University , Takeda Pharmaceutical Company Limited
Inventor： Takanori TAKEBE , Norikazu SAIKI
CPC classification number: G01N33/5014 , C12N5/0634 , C12N5/0697 , G01N33/5082 , C12N2503/04 , C12N2513/00 , G01N2500/10
Abstract: The present invention provides drug toxicity evaluation platforms (such as an evaluation method and a kit therefor) that enable detailed analysis of the possibility and the like of developing drug-induced damage (such as DILI) to the liver and other organs. The method for evaluating drug toxicity of the present invention includes: a step of adding a drug to a co-culture system of an organoid and blood cells; and a step of evaluating the toxicity of the drug to the organoid.
-
公开(公告)号：US20240124593A1
公开(公告)日：2024-04-18
申请号：US18347626
申请日：2023-07-06
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Daniel J. Sexton , Christopher TenHoor , Malini Viswanathan
IPC: C07K16/28 , A61K39/395 , A61K48/00 , A61K49/00 , G01N33/68
CPC classification number: C07K16/283 , A61K39/3955 , A61K48/00 , A61K49/0002 , G01N33/6854 , A61K2039/505
Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
-
公开(公告)号：US11958845B2
公开(公告)日：2024-04-16
申请号：US17952546
申请日：2022-09-26
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masahiro Ito , Hideyuki Sugiyama , Takeshi Yamamoto , Keiko Kakegawa , Jinxing Li , Junsi Wang , Takahito Kasahara , Masato Yoshikawa
IPC: C07D413/14 , A61P25/28 , C07D413/10
CPC classification number: C07D413/14 , A61P25/28 , C07D413/10
Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US11957867B2
公开(公告)日：2024-04-16
申请号：US16310916
申请日：2017-06-26
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Scott Richard Ariagno , Angela Teresa Muriset , Daniel Edward Roush , Denise A. Alexander , Madeleine Clare Gibson , Gin-Fu Chen
CPC classification number: A61M5/008 , A61M5/3129 , A61M5/315 , A61M2005/3139 , A61M2025/024 , A61M2025/028 , A61M2205/586
Abstract: A syringe stabilizing apparatus has a base and a syringe support. The syringe support is vertically disposed above the base, elevating a fluid-filled portion of an infusion set vertically above the base and orienting a delivery end of the fluid-filled portion upwardly relative to a horizontal plane to take advantage of a gravitational effect on a fluid during delivery of the fluid from the fluid-filled portion to a patient. The syringe support comprises a first retainer and a selectively actuated tube clamp. The first retainer has an opening in which a rigid portion of the infusion set is received and retained therein without further user intervention. The selectively actuated tube clamp is operatively aligned with the first retainer. A flexible tube extending from the rigid portion of the infusion set extends through the selectively actuated tube clamp.
-
-
-
-
-
-
-
-
-
Search Results
2080
records
(took 0.188 seconds)
